Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs for Diabetic Nephropathy
NCT07822152Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in diabetic nephropathy (DN) comparing UC-MSCs with Placebo (2 arms). Primary endpoint: Adverse Events at 48 weeks. Started Mar 2026; status: recruiting.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT07822152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07822152.